Hypoglycemia in Type 2 Diabetes Patients Substituted with Insulin Degludec Aspart from Premixed Insulin Therapy: a Quasi Experimental Study
DOI:
https://doi.org/10.51253/pafmj.v74i2.9745Keywords:
Biphasic Insulin Aspart, Glycemic Control, Insulin Degludec Aspart, Type 2 Diabetes MellitusAbstract
Objective: To determine whether Insulin Degludec Aspart is associated with a reduced risk of hypoglycemia as compared to
premixed Insulin aspart therapy in type-2 diabetes mellitus patients.
Study Design: Quasi-experimental study
Place and Duration of Study: Department of Pharmacology, Army Medical College, National University of Medical Sciences,
Rawalpindi and Department of Medicine, Pak Emirates Military Hospital, Rawalpindi Pakistan, from Sep to Dec 2021.
Methodology: One hundred twenty participants with documented type 2 diabetes, taking premixed Insulin Aspart therapy,
were enrolled in the study. The participants were divided into two groups. Group-A participants were continued on Premixed
Insulin Aspart therapy, and Group-B participants were substituted with Insulin Degludec Aspart. The symptomatic
hypoglycemic episodes were recorded for 12 weeks as confirmed hypoglycemia, nocturnal hypoglycemia, and severe
hypoglycemia.
Results: Among the Premixed Insulin Aspart-Group, 49(81.6%) participants and in the Insulin Degludec Aspart-Group,
26(43.3%) participants reported 160 and 40 episodes of confirmed total hypoglycemia, respectively (p-value<0.001). 43(71.6%)
participants in the Premixed Insulin Aspart-Group and 11(18.3%) participants in the Insulin Degludec Aspart-Group reported
73 and 12 episodes of confirmed nocturnal hypoglycemia, respectively (p-value<0.001). No severe hypoglycemic episodes
were recorded in both groups after 12 weeks.
Conclusion: The use of Degludec Aspart is associated with a reduced incidence of hypoglycemia, offering improved treatment
compliance among the Pakistani population with type 2 diabetes.
Downloads
References
Fulcher G, Mehta R, Fita EG, Ekelund M, Bain SC. Efficacy and
Safety of IDegAsp Versus BIAsp 30, Both Twice Daily, in Elderly
Patients with Type 2 Diabetes: Post Hoc Analysis of Two Phase 3
Randomized Controlled BOOST Trials. Diabetes Ther 2019;
(1): 107-118. https://doi.org/10.1007/s13300-018-0531-0
Davies MJ, D'Alessio DA, Fradkin J. Management of
Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report
by the American Diabetes Association (ADA) and the European
Association for the Study of Diabetes (EASD). Diabetes Care
; 41(12): 2669-2701. https://doi.org/10.2337/dci18-0033
Dixit JV, Giri PA, Badgujar SY. 'Daily 2-only meals and exercise'
lifestyle modification for remission of type 2 diabetes mellitus: A
therapeutic approach. J Family Med Prim Care 2022; 11(9): 5700-
https://doi.org/ 10.4103/jfmpc.jfmpc_129_22
Lagani V, Chiarugi F, Thomson S. Development and validation
of risk assessment models for diabetes-related complications
based on the DCCT/EDIC data. J Diabetes Complications 2015;
(4): 479-487. https://doi.org/ 10.1016/j.jdiacomp.2015.03.001
Vamvini MT, Dushay JR, Abrahamson MJ. Virtually Better
Diabetes Care?. Clin Diabetes. 2019; 37(3): 284-286.
https://doi.org/10.2337/cd18-0052
Castellana M, Procino F, Sardone R, Trimboli P, Giannelli G.
Efficacy and safety of patient-led versus physician-led titration
of basal insulin in patients with uncontrolled type 2 diabetes: a
meta-analysis of randomized controlled trials. BMJ Open
Diabetes Res Care 2020; 8(1): e001477.
https://doi.org/10.1136/bmjdrc-2020-001477
Haluzík M, Fulcher G, Pieber TR, Bardtrum L, Tutkunkardas D,
Rodbard HW, et al. The co-formulation of insulin degludec and
insulin aspart lowers fasting plasma glucose and rates of
confirmed and nocturnal hypoglycaemia, independent of
baseline glycated haemoglobin levels, disease duration or body
mass index: A pooled meta-analysis of phase III studies in
patients with type 2 diabetes. Diabetes Obes Metab 2018; 20(7):
-1592. https://doi.org/10.1111/dom.13261
Moon S, Chung HS, Kim YJ. Efficacy and Safety of Insulin
Degludec/Insulin Aspart Compared with a Conventional
Premixed Insulin or Basal Insulin: A Meta-Analysis. Metabolites
; 11(9): 639. https://doi.org/10.3390/metabo11090639
Kalra S, Atkin S, Cervera A. Multinational Consensus: Insulin
Initiation with Insulin Degludec/Aspart (IDegAsp) Adv Ther
; 35(7): 928-936. https://doi.org/10.1007/s12325-018-0712-2
Fujimoto K, Iwakura T, Aburaya M, Matsuoka N. Twice-daily
insulin degludec/insulin aspart effectively improved morning
and evening glucose levels and quality of life in patients
previously treated with premixed insulin: an observational
study. Diabetol Metab Syndr 2018; 10: 64.
https://doi.org/10.1186/s13098-018-0366-x
Özçelik S, Çelik M, Vural A, Aydın B, Özçelik M, Gozu H, et al.
Outcomes of transition from premixed and intensive insulin
therapies to insulin aspart/degludec co-formulation in type 2
diabetes mellitus: a real-world experience. Arch Med Sci 2020;
(1): 1-8. https://doi.org/10.5114/aoms.2020.93264
Cho KY, Nakamura A, Oba-Yamamoto C. Switching to OnceDaily Insulin Degludec/Insulin Aspart from Basal Insulin
Improves Postprandial Glycemia in Patients with Type 2
Diabetes Mellitus: Randomized Controlled Trial. Diabetes Metab
J 2020; 44(4): 532-541. https://doi.org/10.4093/dmj.2019.0093
Lane WS, Favaro E, Rathor N. A Randomized Trial Evaluating
the Efficacy and Safety of Fast-Acting Insulin Aspart Compared
With Insulin Aspart, Both in Combination With Insulin
Degludec With or Without Metformin, in Adults With Type 2
Diabetes (ONSET 9). Diabetes Care 2020; 43(8): 1710-1716.
https://doi.org/10.2337/dc19-2232
Haahr H, Fita EG, Heise T. A Review of Insulin
Degludec/Insulin Aspart: Pharmacokinetic and
Pharmacodynamic Properties and Their Implications in Clinical
Use. Clin Pharmacokinet 2017; 56(4): 339-354.
Downloads
Published
Issue
Section
How to Cite
